Literature DB >> 22730109

Multidisciplinary therapy consisting of minimally invasive resection, irradiation, and intra-arterial infusion of 5-fluorouracil for maxillary sinus carcinomas.

Hiroshi Nishino1, Minako Takanosawa, Kazumi Kawada, Takeharu Kanazawa, Keiichi Ichimura, Satoru Takahashi, Masanori Nakazawa.   

Abstract

BACKGROUND: Current goals for the treatment of maxillary sinus carcinoma include the preservation of vision, eating, communication, and appearance, as well as the achievement of a cure.
METHODS: Japanese patients (n = 121) with maxillary sinus carcinoma were analyzed retrospectively. All patients underwent multidisciplinary therapy including minimally invasive resection, 20 Gy irradiation, and intra-arterial infusion of 5-fluorouracil.
RESULTS: The 5- and 10-year overall survival rates were 73% and 68%, respectively. In 97 patients with squamous cell carcinoma (SCC), the 5- and 10-year overall survival rates were 76% and 70%, respectively. All 29 patients with orbital invasion retained the orbital contents, and 21 of these patients demonstrated adequate visual acuity. There were 16 complications, including trismus (5 patients), double vision (5 patients), fistula formation (3 patients), and cataract (3 patients).
CONCLUSION: A multidisciplinary therapy, consisting of minimally invasive resection, irradiation, and regional chemotherapy, can yield good patient prognosis and quality of life after treatment.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22730109     DOI: 10.1002/hed.23030

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  1 in total

1.  Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation.

Authors:  Chan-Young Ock; Bhumsuk Keam; Tae Min Kim; Doo Hee Han; Tae-Bin Won; Se-Hoon Lee; J Hun Hah; Tack-Kyun Kwon; Dong-Wan Kim; Dong-Young Kim; Chae-Seo Rhee; Hong-Gyun Wu; Myung-Whun Sung; Dae Seog Heo
Journal:  Korean J Intern Med       Date:  2016-03-15       Impact factor: 2.884

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.